Linsitinib-mediated IGF-1R inhibition was confirmed by immunoblot analysis of IGF-1R, AKT, and cleaved PARP in residual cancer cells, while apoptosis was quantified by flow cytometry of GFP-labeled cells; delayed tumor recurrence upon KRAS reactivation validated dormancy eradication in vivo. Here, KRAS is linked to cancer.